Trial Profile

A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination doses of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Jan 2026 According to a GSK plc media release, company has announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, has been approved by the European Commission (EC) for use in adults aged 18 years and older.
08 Oct 2024 Results published in a GSK plc media release
08 Oct 2024 According to a GSK plc media release, new data from AReSVi-006 trial will be presented today at the CHEST 2024 Annual Meeting, organised by the American College of Chest Physicians. In addition to the presentation at CHEST, the data will be submitted for scientific peer-reviewed publication and to regulators for review.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com